Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 8/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CYBB | P04839 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | SNCA | P37840 | 1/20 | 0.52 |
| ▸ | NOX3 | Q9HBY0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355925 | 1.00 | TP53 (0.78) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL11386797 | 0.90 | TP53 (0.64) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL11396917 | 0.87 | TP53 (0.61) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL29441734 | 0.85 | TP53 (0.59) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL17085962 | 0.85 | TP53 (0.59) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL18381705 | 0.84 | TP53 (0.67) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL16291336 | 0.84 | HPGD (0.66) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL4670438 | 0.84 | HPGD (0.70) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL18381597 | 0.83 | TP53 (0.65) | TP53POLBL3MBTL1THRBBLM | |
| SCHEMBL18381732 | 0.81 | TP53 (0.67) | TP53POLBL3MBTL1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814376-B2 | Hepatitis b core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-27 | — | — | US | disclosed |
| EP-3349761-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3349581-B1 | HEPATITIS B CORE PROTEIN MODULATORS | ASSEMBLY BIOSCIENCES INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10987360-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-01-19 | — | — | US | disclosed |
| WO-2015138895-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-17 | — | — | WO | disclosed |
| EP-1937614-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | Arcadia Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047776-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047776-A1 | IRON CATALYZED CROSS-COUPLING REACTIONS OF IMIDOYL DERIVATIVES | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | TP53 4530/4885POLB 1159/4885L3MBTL1 3702/4885 |
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | TP53 4870/4885POLB 4785/4885L3MBTL1 4747/4885 |
| US-20170015658-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | TP53 602/4885POLB 2239/4885L3MBTL1 1979/4885 |
| US-10987360-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | TP53 724/4885POLB 1770/4885L3MBTL1 2994/4885 |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | TP53 602/4885POLB 2239/4885L3MBTL1 1979/4885 |
| US-20240025890-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | TP53 411/4885POLB 1965/4885L3MBTL1 1920/4885 |
| US-20230044112-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | TP53 411/4885POLB 1965/4885L3MBTL1 1920/4885 |
| US-11814376-B2 | Hepatitis b core protein modulators | HAVCR2, FABP1, MAVS | TP53 411/4885POLB 1965/4885L3MBTL1 1920/4885 |
| US-20220023311-A1 | HEPATITIS B CORE PROTEIN MODULATORS | HAVCR2, FABP1, MAVS | TP53 724/4885POLB 1770/4885L3MBTL1 2994/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | TP53 4870/4885POLB 4785/4885L3MBTL1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.